# Relay Therapeutics, Inc. (RLAY) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Relay Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/RLAY/mda/fy2025/): filed 2026-02-26; accession 0001193125-26-076739 (https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/rlay-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/RLAY/mda/fy2024/): filed 2025-02-26; accession 0000950170-25-027756 (https://www.sec.gov/Archives/edgar/data/1812364/000095017025027756/rlay-20241231.htm)
- [FY 2023 MD&A](/company/RLAY/mda/fy2023/): filed 2024-02-22; accession 0000950170-24-018797 (https://www.sec.gov/Archives/edgar/data/1812364/000095017024018797/rlay-20231231.htm)
- [FY 2022 MD&A](/company/RLAY/mda/fy2022/): filed 2023-02-23; accession 0000950170-23-004123 (https://www.sec.gov/Archives/edgar/data/1812364/000095017023004123/rlay-20221231.htm)
- [FY 2021 MD&A](/company/RLAY/mda/fy2021/): filed 2022-02-24; accession 0000950170-22-001978 (https://www.sec.gov/Archives/edgar/data/1812364/000095017022001978/rlay-20211231.htm)

Back to /company/RLAY/